<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Gyre Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/gyre-therapeutics-inc</link>
<description>Latest news and press releases for Gyre Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/gyre-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357be178dffbe2df0f982f.webp</url>
<title>Gyre Therapeutics, Inc.</title>
<link>https://6ix.com/company/gyre-therapeutics-inc</link>
</image>
<item>
<title>Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment</guid>
<pubDate>Tue, 12 May 2026 20:05:00 GMT</pubDate>
<description>SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is l</description>
</item>
<item>
<title>Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update</guid>
<pubDate>Thu, 07 May 2026 10:00:00 GMT</pubDate>
<description>Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s CDE in March 2026 Completed acquisition of Cullgen in an approximately $300 million all-stock transaction, expanding pipeline into inflammatory diseases and cancers First patient enrolled in Phase 2/3 trial evaluating ETUARY™ for radiation-induced lung injury, including immune-related pneum</description>
</item>
<item>
<title>Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-completes-acquisition-of-cullgen-to-create-us-and-china-based-fully-integrated-biopharmaceutical-company</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-completes-acquisition-of-cullgen-to-create-us-and-china-based-fully-integrated-biopharmaceutical-company</guid>
<pubDate>Mon, 04 May 2026 12:47:00 GMT</pubDate>
<description>Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates. Strengthened leadership team in U.S., coupled with China operating presence to support future global growth. SAN DIEGO, May</description>
</item>
<item>
<title>Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-chinas-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-chinas-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial</description>
</item>
<item>
<title>Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0</description>
</item>
<item>
<title>Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-protein-degradation-platform-and-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-protein-degradation-platform-and-pipeline</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline of</description>
</item>
<item>
<title>Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-alignment-chinas-cde-conditional-approval-pathway-and</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-alignment-chinas-cde-conditional-approval-pathway-and</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing</description>
</item>
<item>
<title>Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-third-quarter-2025-and-year-date-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-third-quarter-2025-and-year-date-financial-results-and</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to</description>
</item>
<item>
<title>Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-completion-patient-enrollment-phase-3-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-completion-patient-enrollment-phase-3-clinical-trial</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to</description>
</item>
<item>
<title>Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-present-results-positive-phase-3-clinical-trial-evaluating</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-present-results-positive-phase-3-clinical-trial-evaluating</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to</description>
</item>
<item>
<title>Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-present-hc-wainwright-27th-annual-global-investment-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-present-hc-wainwright-27th-annual-global-investment-conference-2025</guid>
<pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated</description>
</item>
<item>
<title>Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-appointment-dan-weng-md-board-directors-2025-08-22</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-appointment-dan-weng-md-board-directors-2025-08-22</guid>
<pubDate>Fri, 22 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to</description>
</item>
<item>
<title>Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-second-quarter-2025-and-year-date-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-second-quarter-2025-and-year-date-financial-results-and</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128</description>
</item>
<item>
<title>Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-first-dosing-phase-1-trial-f230-pulmonary-arterial</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-first-dosing-phase-1-trial-f230-pulmonary-arterial</guid>
<pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to</description>
</item>
<item>
<title>Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-closing-its-public-offering-and-full-exercise</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-closing-its-public-offering-and-full-exercise</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to</description>
</item>
<item>
<title>Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-pricing-200-million-public-offering-common-stock-2025-05</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-pricing-200-million-public-offering-common-stock-2025-05</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ</description>
</item>
<item>
<title>Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-proposed-underwritten-public-offering-common-stock-2025</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-proposed-underwritten-public-offering-common-stock-2025</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ</description>
</item>
<item>
<title>Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-hydronidone-met-primary-endpoint-and-demonstrated-statistically</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-hydronidone-met-primary-endpoint-and-demonstrated-statistically</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrated favorable safety and</description>
</item>
<item>
<title>Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
<description>Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data</description>
</item>
<item>
<title>Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications</title>
<link>https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-nmpa-approval-clinical-trial-evaluating-pirfenidone</link>
<guid isPermaLink="true">https://6ix.com/company/gyre-therapeutics-inc/news/gyre-therapeutics-announces-nmpa-approval-clinical-trial-evaluating-pirfenidone</guid>
<pubDate>Mon, 31 Mar 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on</description>
</item>
</channel>
</rss>